Skip to main content
SpringerLink
Log in

Immunosuppressive Medications

  • Reference work entry
  • First Online:
Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care

  • 435 Accesses

Abstract

Immunosuppression following pediatric thoracic transplantation is typically centered on the use of calcineurin inhibitors, either cyclosporine or tacrolimus. While there is general agreement on the use of immunosuppressive medications for induction therapy, maintenance immunosuppression, and treatment of acute rejection, there is center-to-center variability with respect to target trough levels, changes in targets over time following transplantation, and selection and use of adjunctive immunosuppressive agents. In this chapter, the medications and therapies used to care for pediatric heart and lung transplant recipients are reviewed and discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 1,299.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,799.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Calne RY, Rolles K, White DJ et al (1979) Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2:1033–1036

    Article  CAS  PubMed  Google Scholar 

  2. Starzl TE, Todo S, Fung JJ et al (1989) FK506 for human liver, kidney, and pancreas transplantation. Lancet 2:1000–1004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kirk R, Edwards LB, Kucheryavaya AY et al (2011) The registry of the International Society for Heart and Lung Transplantation: fourteenth pediatric heart transplantation report—2011. J Heart Lung Transplant 30:1095–1103

    Article  PubMed  Google Scholar 

  4. Groetzner J, Meiser B, Landwehr P et al (2004) Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 77:568–574

    Article  CAS  PubMed  Google Scholar 

  5. Groetzner J, Kaczmarek I, Schulz U et al (2009) Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 87:726–733

    Article  CAS  PubMed  Google Scholar 

  6. Flechner SM, Kobashigawa J, Klintmalm G (2008) Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22:1–15

    Article  PubMed  Google Scholar 

  7. Thomson AW, Bonham CA, Zeevi A (1995) Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 17:584–591

    Article  CAS  PubMed  Google Scholar 

  8. Kobashigawa JA, Patel J, Furukawa H et al (2006) Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 25:434–439

    Article  PubMed  Google Scholar 

  9. Pirsch JD, Miller J, Deierhoi MH et al (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977–983

    Article  CAS  PubMed  Google Scholar 

  10. Taketomo CK, Hodding JH, Kraus DM (2011–2012) Pediatric & neonatal dosage handbook, 19th edn. Lexicomp, Hudson, OH

    Google Scholar 

  11. Krämer BK, Charpentier B, Bäckman L et al (2010) Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 10:2632–2643

    Article  PubMed  Google Scholar 

  12. Han DJ, Park JB, Kim YS et al (2012) A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. Transplant Proc 44:115–117

    Article  CAS  PubMed  Google Scholar 

  13. Robinson BV, Boyle GJ, Miller SA, Law Y, Griffith BP, Webber SA (1999) Optimal dosing of intravenous tacrolimus following pediatric heart transplantation. J Heart Lung Transplant 18:786–791

    Article  CAS  PubMed  Google Scholar 

  14. Pitzalis C, Pipitone N, Bajocchi G et al (1997) Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. J Immunol 158:5007–5016

    CAS  PubMed  Google Scholar 

  15. Kasiske BL, Chakkera HA, Louis TA et al (2000) A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11:1910–1917

    CAS  PubMed  Google Scholar 

  16. Vincenti F, Schena FP, Paraskevas S et al (2008) A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 8:307–316

    Article  CAS  PubMed  Google Scholar 

  17. Lindenfeld J, Miller GG, Shakar SF et al (2004) Drug therapy in the heart transplant recipient. Part I: cardiac rejection and immunosuppressive drugs. Circulation 110:3734–3740

    Article  PubMed  Google Scholar 

  18. Munoz R, Schmitt C, Roth S et al (2008) Handbook of pediatric cardiovascular drugs. Springer-Verlag, London

    Book  Google Scholar 

  19. Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715–2729

    Article  CAS  PubMed  Google Scholar 

  20. Merrill JP, Murray JE, Harrison JH et al (1960) Successful homotransplantations of the kidney between non-identical twins. N Engl J Med 262:1251–1260

    Article  Google Scholar 

  21. Starzl TE, Marchioro TL, Waddell WR (1963) The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 117:385–395

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al (2003) Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 3:68–73

    Article  CAS  PubMed  Google Scholar 

  23. Gourishankar S, Hunsicker LG, Jhangri GS et al (2003) The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 14:2387–2394

    Article  PubMed  Google Scholar 

  24. Kobashigawa J, Miller L, Renlund D et al (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66:507–515

    Article  CAS  PubMed  Google Scholar 

  25. Shihab FS, Bennett WM, Yi H et al (2004) Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 65:1262–1271

    Article  CAS  PubMed  Google Scholar 

  26. Kuppahally S, Al-Khaldi A, Weisshaar D et al (2006) Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 6:986–992

    Article  CAS  PubMed  Google Scholar 

  27. Eisen HJ, Tuzcu EM, Dorent R et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349:847–858

    Article  CAS  PubMed  Google Scholar 

  28. Meiser BM, Billingham ME, Morris RE (1991) Effects of cyclosporine, FK506, and rapamycin on graft-vessel disease. Lancet 338:1297–1298

    Article  CAS  PubMed  Google Scholar 

  29. Lobach N, Pollock-BarZiv S, West L et al (2005) Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant 24:184–189

    Article  PubMed  Google Scholar 

  30. Behnke-Hall K, Bauer J, Akintuerk H et al (2011) Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus. Pediatr Transplant 15:784–789

    Article  CAS  PubMed  Google Scholar 

  31. Nashan B (2005) Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs 19:39–46

    Article  CAS  PubMed  Google Scholar 

  32. Lundquist AL, Chari RS, Wood JH et al (2007) Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 13:647–650

    Article  PubMed  Google Scholar 

  33. Woodside KJ, Lick SD (2007) Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant 26:750–752

    Article  PubMed  Google Scholar 

  34. Das B, Shoemaker L, Recto M et al (2008) Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant 27:242–244

    Article  PubMed  Google Scholar 

  35. McCurry KR, Iacono A, Zeevi A et al (2005) Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 130:528–537

    Article  PubMed  PubMed Central  Google Scholar 

  36. Campath® (ALEMTUZUMAB) [package insert]. Millennium and ILEX Partners, LP, Cambridge, MA

    Google Scholar 

  37. Morris PJ, Russel NK (2006) Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 81:1361–1367

    Article  PubMed  Google Scholar 

  38. Vincenti F, Larsen C, Durrbach A et al (2005) Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353:770–781

    Article  CAS  PubMed  Google Scholar 

  39. Vincenti F, Dritselis A, Kirkpatrick P (2011) Belatacept. Nat Rev Drug Discov 10:655–656

    Article  CAS  PubMed  Google Scholar 

  40. Vincenti F, Charpentier B, Vanrenterghem Y et al (2010) A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10:535–546

    Article  CAS  PubMed  Google Scholar 

  41. Korom S (2009) Immunosuppression in cardiac transplantation: state of the art and new drugs. Kardiovaskuläre Medizin 12:272–276

    Google Scholar 

  42. Mehra MR, Zucker MJ, Wagoner L et al (2005) A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 24:1297–1304

    Article  PubMed  Google Scholar 

  43. Mattei MF, Redonnet M, Gandjbakhch I et al (2007) Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 26:693–699

    Article  PubMed  Google Scholar 

  44. Chou NK, Wang SS, Chen YS et al (2008) Induction immunosuppression with basiliximab in heart transplantation. Transplant Proc 40:2623–2625

    Article  CAS  PubMed  Google Scholar 

  45. Kobashigawa J, Crespo-Leiro MG, Ensminger SM et al (2010) Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 30:252–269

    Article  Google Scholar 

  46. Tambur A, Pamboukian SV, Costanzo M et al (2005) The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 80:1019–1025

    Article  PubMed  Google Scholar 

  47. Colvin RB, Smith RN (2005) Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5:807–817

    Article  CAS  PubMed  Google Scholar 

  48. Jordan S, Cunningham-Rundles C, McEwan R (2003) Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 3:653–664

    Article  PubMed  Google Scholar 

  49. Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484–486

    Article  CAS  PubMed  Google Scholar 

  50. Toyoda M, Pao A, Petrosian A et al (2003) Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 3:156–166

    Article  CAS  PubMed  Google Scholar 

  51. FDA. US Food and Drug Administration (2012) FDS labeling information – Velcade. FDA website [online], http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021602s027lbl.pdf

  52. Morrow WR, Frazier EA, Mahle WT et al (2012) Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 93:319–324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Patel J, Everly M, Chang D et al (2011) Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant 30:1320–1326

    Article  PubMed  Google Scholar 

  54. Locke E, Magra CM, Singer DL et al (2009) The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 9:231–35

    Article  CAS  PubMed  Google Scholar 

  55. Dawson KL, Parulekar A, Seethamraju H (2012) Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J Heart Lung Transplant 31:1325–6

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacy Specialist, Cardiac Intensive Care, Department of Pharmacy, Children’s Hospital of Pittsburgh of UPMC, 4401 Penn Ave., Pittsburgh, PA, 15224, USA

    Donald Berry

  2. Heart Failure and Cardiac Transplantation, Children’s Hospital of Pittsburgh of UPMC, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

    Brian Feingold

Authors
  1. Donald Berry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian Feingold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald Berry .

Editor information

Editors and Affiliations

  1. Dept. of Pediatric Cardiology, Children's Hospital Colorado, Univ. of Colorado, Denver, Aurora, Colorado, USA

    Eduardo M. Da Cruz

  2. Dept. Pediatric Cardiology, Children's Hospital Colorado, Univ. of Colorado, Denver, Aurora, Colorado, USA

    Dunbar Ivy

  3. Pediatric Cardiac Surgery, Children's Hospital Colorado, Univ. of Colorado, Denver, Aurora, Colorado, USA

    James Jaggers

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this entry

Cite this entry

Berry, D., Feingold, B. (2014). Immunosuppressive Medications. In: Da Cruz, E., Ivy, D., Jaggers, J. (eds) Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. Springer, London. https://doi.org/10.1007/978-1-4471-4619-3_133

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4619-3_133

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4618-6

  • Online ISBN: 978-1-4471-4619-3

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation